pharmacology

pharmacology

pharmacology

A study involving 100,000 people shows that they all carry genetic variants that may influence their response to medicines

Pharmacogenomics studies how certain genes in a person – known as pharmacogenes – influence their response to medicines and the way in which the body metabolises them. One of the obstacles to its widespread adoption is the lack of diversity in research, as there is a scarcity of genetic data on groups of African and non-European descent. Now, a study published in Science Translational Medicine has analysed genetic and medication data from a diverse group of nearly 100,000 Americans participating in the All of Us medical initiative. 100 per cent had at least one variant in one of the 16 pharmacogenes, and 24.4 per cent had taken a medicine whose effect would be affected by one of those variants.

0

Some antidepressants may be more effective than others in the long term

A review published in The Lancet Psychiatry shows that some antidepressants, such as escitalopram and duloxetine, may be more effective than fluoxetine at helping people with depression to improve and to remain on treatment in the long term — typically for around six months. The study, which pooled the results of 115 randomised controlled trials on 21 antidepressants involving more than 30,000 people, is the first to compare the long-term efficacy — over more than 12 weeks — of different antidepressants.

 

0

Results are presented from the unsuccessful first clinical trial that aimed to reduce cardiovascular risk by lowering lipoprotein(a) levels

The HORIZON trial was the first to evaluate the potential effect on cardiovascular risk of a drug—pelacarsen—that reduces lipoprotein(a) levels in the blood. While this approach had generated high expectations, it did not prove successful in this trial, which involved 8,000 patients who had already experienced cardiovascular events. The negative results, which Novartis previewed in a press release in September, are being presented in full on November 7 at the American Heart Association congress and are published in NEJM.

0

Lipoprotein (a): what we know about the new hope for cardiovascular health and its publicised failure

Lipoprotein (a) is a particle that is very similar to, but distinct from, LDL, the ‘bad cholesterol’. Regarded as the hidden factor in cardiovascular risk, some scientific societies recommend that it be measured at least once in a person’s lifetime. The problem is that there are no treatments based on it to reduce the risk of heart attacks or strokes. This summer, the first clinical trial involving one of the drugs under investigation was completed and, contrary to expectations, the pharmaceutical company Novartis announced that the trial had failed: the reduction in lipoprotein (a) did not improve the participants’ health. The full results, which may call into question a long-accepted theory, will be presented on Saturday 7 November at the American Heart Association’s annual meeting.

0

A new drug shows efficacy against advanced endometrial cancer, according to a phase 3 trial

The incidence of and mortality from endometrial cancer (cancer of the uterine lining) have been rising in recent years. When diagnosed at an advanced stage, the prognosis is very poor. A phase 3 clinical trial, coordinated across nearly 30 countries—including Spain—has tested a new treatment for patients whose cancer has progressed following chemotherapy and immunotherapy. The drug combines an antibody designed to target the tumor with a chemotherapy agent that is released once the antibody binds to the tumor cells. The trial, which involved 776 women, showed that the new treatment reduced the risk of cancer progression by 41% and the risk of death by 32% during the study period, compared to standard treatment. The findings are being presented at ESMO, the European Society for Medical Oncology congress currently taking place in Madrid, and are being published simultaneously in The Lancet. 

0

The results of the personalised melanoma vaccine will be presented at the european congress of medical oncology

The administration of intismeran, a personalised therapeutic cancer vaccine developed from each patient’s tumour, together with pembrolizumab immunotherapy following surgery for high-risk melanoma, reduced the risk of recurrence or death by 42 per cent. This phase 3 clinical trial, funded by Moderna and Merck Sharp & Dohme, involved 1,137 patients at very high risk of recurrence who had undergone surgical removal of their melanoma. The companies released preliminary data in August in a press release, and the full results are due to be presented this Saturday at the European Society for Medical Oncology (ESMO) Congress being held in Madrid. Ahead of the announcement, the data were leaked yesterday and the share prices of both companies fell. The scientific paper is due to be published in The New England Journal of Medicine.

0

Weight loss alone does not explain the lower incidence of heart disease in people taking semaglutide

Semaglutide is known to reduce the risk of serious heart disease, but a study published in the European Heart Journal suggests that this effect cannot be explained by weight loss alone. The researchers analysed known risk factors for heart disease, such as body weight and waist circumference, in patients taking part in a clinical trial of semaglutide. Although the risk of serious cardiovascular disease was lower among those taking the drug, only half of this reduction could be explained by changes in these risk factors.

0

A study suggests that stopping statin treatment in people aged 75 and over with no history of heart disease or stroke does not increase the risk of death

Statins are used to prevent atherosclerotic cardiovascular disease (ACD), a specific type of cardiovascular disease caused by the build-up of fatty plaque inside the arteries, which can lead to heart disease or stroke. A study published in The Lancet Healthy Longevity analysed the effect of stopping statins in adults aged 75 and over who were taking them preventatively, that is, without a history of atherosclerotic cardiovascular disease. The results showed that discontinuing treatment was no worse than continuing it in terms of all-cause mortality over a three-year period. According to the authors, these results support individualised decision-making regarding the discontinuation of statin treatment in older people, rather than a blanket recommendation to stop taking them.

0

A single dose of rapamycin in mice reduces behaviours similar to those seen in the autism spectrum for a few hours

A team from the United States exposed pregnant mice to a mild inflammatory agent so that their offspring would develop brain and behavioural changes similar to those seen in autism spectrum disorder. When these offspring reached adulthood, the researchers administered a dose of rapamycin — an immunosuppressant — and found that several of these changes improved for a few hours, including cerebral hyperactivity, the risk of seizures, sensory hypersensitivity, repetitive behaviours and abnormal organisation of the brain’s functional network. The authors, whose work is published in Nature Communications, emphasise in a press release that these effects are temporary and that repeated administration loses its efficacy. Furthermore, they point out that rapamycin’s high potential for toxicity and the fact that the study was conducted on mice rule out its widespread use in humans.

 

 

0

Of mice and men: what you need to know when a treatment is reported to have been successful in laboratory animals

We often see headlines claiming that new research has found a ‘cure’ for diseases. However, what are the real chances of this being true? How does the current stage of the research affect its ultimate outcome? Has it already been tested on humans, or only on laboratory animals? In this article, we explain why animals are used in biomedicine, the reasons why mice are the most commonly used, the steps and timeframes involved from when a treatment appears effective until it can be determined whether it works in people, the characteristics and limitations of various disease models, and how results should be communicated to inform the public without raising false hopes.

0